Impact of salvage chemotherapy after immune checkpoint inhibitor for recurrent or metastatic head and neck cancer.
Takuma MatobaKiyoshi MinoharaDaisuke KawakitaMichi SawabeGaku TakanoKeisuke OguriAkihiro MurashimaSho IwakiHiroshi TsugeSae ImaizumiWataru HojoAyano KondoKoji TsukamotoShinichi IwasakiPublished in: Head & neck (2024)
SCT can improve the survival outcomes of patients with RM-HNC. In addition to PTX and Cmab, PTX monotherapy is also considered an effective SCT regimen. SCT is effective regardless of the presence or absence of irAEs.